Oral anticoagulation provides robust protection against cardioembolic events in patients diagnosed with atrial fibrillation. However, clinicians continue to encounter individuals who develop a breakthrough ischemic stroke despite therapeutic anticoagulation. Managing this complex clinical cohort presents formidable diagnostic and therapeutic challenges for neurologists and cardiologists alike. Breakthrough strokes often stem from competing vascular etiologies rather than pure anticoagulant failure. Furthermore, the anatomical distribution of the cerebral infarct substantially influences subsequent patient recovery and vascular risk. Understanding the prognostic differences between posterior and anterior circulation infarctions remains vital for optimizing secondary prevention and clinical survival.

Clinical Significance of Breakthrough Ischemic Stroke by Arterial Territory

Breakthrough ischemic stroke during ongoing oral anticoagulation represents a major therapeutic dilemma. Historically, clinicians assumed that anterior circulation infarcts yielded poorer functional outcomes due to extensive cortical involvement and prominent hemispheric deficits. Anterior strokes typically trigger hemiparesis, severe aphasia, and noticeable functional impairment. Consequently, emergency medical systems prioritize rapid anterior territory recanalization. In contrast, posterior circulation infarctions involve the brainstem, cerebellum, and occipital lobes, presenting with vertigo, ataxia, or visual field deficits. These subtle, fluctuating symptoms frequently delay hospital presentation and diagnostic imaging. Furthermore, posterior circulation territories exhibit distinct hemodynamic vulnerabilities and vascular geometries that complicate acute management. Large-artery atherosclerosis frequently affects the basilar and vertebral arteries, creating severe local stenosis alongside cardioembolic risk. Therefore, stroke teams must evaluate posterior ischemic events through a specialized prognostic lens. In addition, prompt vascular imaging helps clinicians identify high-risk arterial lesions requiring intensified medical therapy. Emerging data confirm that posterior strokes signal extensive vascular instability and heightened susceptibility to recurring thromboembolic insult.

Baseline Disparities Between Posterior and Anterior Infarct Populations

The ASPERA-R study analyzed 1,649 patients with atrial fibrillation who experienced acute ischemic stroke despite documented oral anticoagulation therapy. Within this multicenter cohort, exactly 165 individuals, representing 10.0% of the study population, suffered a posterior circulation infarct. Interestingly, researchers observed notable baseline differences when comparing posterior and anterior circulation cohorts. Patients with posterior circulation infarcts presented with significantly lower initial stroke severity on admission, as reflected by lower baseline neurological deficit scores. Furthermore, clinicians observed that patients in the posterior circulation group were more frequently taking vitamin K antagonists rather than direct oral anticoagulants. Because international normalized ratio values often fluctuate, subtherapeutic anticoagulation may have contributed to clot formation in these patients. However, baseline vascular risk factors, including hypertension and diabetes mellitus, remained highly prevalent across both clinical cohorts. These distinct baseline profiles highlight the complex pathophysiological environment surrounding breakthrough events. Thus, clinicians cannot rely on mild initial stroke presentation alone to predict favorable long-term recovery.

ASPERA-R Methodology and Inverse Probability Weighting Analysis

Observational stroke registries inevitably face substantial confounding due to baseline imbalances between anatomical groups. To address this methodological challenge, the ASPERA-R investigators employed inverse probability weighting with truncation of extreme weights. Furthermore, the research team implemented additional multivariable adjustments to eliminate residual confounding factors across demographic and clinical variables. This rigorous analytical design effectively balanced critical covariates, including age, comorbid cardiovascular conditions, baseline disability, and pre-stroke anticoagulant classes. Consequently, the statistical model created pseudo-populations with balanced baseline prognostic characteristics, mimicking randomized clinical conditions. In observational research, crude outcome comparisons often mislead clinicians because sicker patients frequently present with specific anatomical patterns. By standardizing these baseline attributes, the researchers isolated the true prognostic impact of infarct location. Moreover, weight truncation prevented individual outliers from exerting disproportionate influence over the estimated hazard ratios. Accordingly, this sophisticated statistical framework provides robust epidemiological evidence regarding clinical trajectories after breakthrough vascular failure. Consequently, clinicians can evaluate therapeutic efficacy without the confounding distortion inherent to unweighted real-world studies.

Evaluating Primary Composite Vascular Endpoints and Functional Trajectories

The primary outcome in the ASPERA-R analysis evaluated a composite endpoint at 90 days. This endpoint comprised recurrent ischemic stroke, acute myocardial infarction, and vascular death. Following propensity weighting, posterior circulation infarcts demonstrated a statistically significant elevation in composite risk compared to anterior circulation events. Specifically, patients with posterior infarcts exhibited an adjusted hazard ratio of 1.50, demonstrating a 50% greater risk of adverse vascular events. In addition, secondary analyses examined functional disability shifts on the modified Rankin Scale alongside overall mortality. Despite presenting initially with milder neurological deficits, posterior circulation stroke patients experienced less favorable long-term functional recovery than anticipated. Persistent cerebellar ataxia, brainstem dysfunction, and chronic equilibrium disorders severely impair daily activities in this population. Furthermore, competing vascular mechanisms, such as intracranial vertebrobasilar stenosis, maintain an elevated risk of secondary ischemic injury. As a result, recurrent thromboembolism and cardiac events accumulate rapidly within the first three months following index admission.

Safety Profiles, Hemorrhagic Risks, and Multidisciplinary Management

Safety considerations remain paramount when clinicians manage patients who develop ischemic strokes while receiving continuous oral anticoagulation. The ASPERA-R study rigorously tracked early 24-hour hemorrhagic transformation, symptomatic intracranial hemorrhage, and 90-day intracerebral hemorrhage rates. Notably, the weighted analysis demonstrated comparable safety profiles between posterior and anterior circulation infarcts. The risk of early hemorrhagic transformation did not increase significantly among patients experiencing posterior territory ischemia. Similarly, rates of symptomatic intracranial hemorrhage remained low across both anatomical cohorts. This finding provides crucial clinical reassurance for practicing physicians. Anticoagulant resumption often triggers clinical hesitation due to intracranial bleeding fears. However, the data indicate that posterior infarct location does not heighten intracranial hemorrhagic vulnerability. Instead, the primary threat driving adverse 90-day outcomes in posterior stroke remains recurrent ischemic thromboembolism. Therefore, secondary prevention strategies should focus decisively on eliminating ischemic recurrence. Clinicians must thoroughly investigate competing stroke mechanisms beyond atrial fibrillation, including intracranial atherosclerosis and drug interactions, while ensuring optimized antithrombotic coverage.

Frequently Asked Questions

What constitutes a breakthrough ischemic stroke in atrial fibrillation?

A breakthrough ischemic stroke occurs when an acute cerebral infarction develops despite documented adherence to continuous oral anticoagulation. Clinicians frequently encounter this complex scenario in patients receiving direct oral anticoagulants or vitamin K antagonists. Consequently, medical teams must evaluate non-cardioembolic causes, drug interactions, and dosing adequacy to guide subsequent secondary prevention strategies.

Why do posterior circulation infarcts carry worse outcomes in breakthrough stroke?

Posterior circulation infarcts often present with non-specific, insidious symptoms that delay acute presentation and reperfusion therapies. Additionally, patients with vertebrobasilar events frequently suffer from severe intracranial atherosclerotic disease and microvascular compromise. Consequently, these competing vascular pathologies elevate the risk of recurrent ischemic events, major vascular complications, and functional disability.

How should clinicians approach secondary prevention after a breakthrough stroke?

Clinicians should systematically investigate competing vascular etiologies, review drug-drug interactions, and confirm patient medication adherence. Furthermore, teams should evaluate whether to switch anticoagulant agents or add selective antiplatelet therapy for confirmed large-artery atherosclerosis. Therefore, tailored multidisciplinary management between neurologists and cardiologists remains essential to reduce vascular mortality and stroke recurrence.

Disclaimer: This content is for informational and educational purposes only and does not substitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Foschi M et al. Posterior versus anterior circulation infarct location and outcomes after breakthrough ischemic stroke in orally anticoagulated patients for atrial fibrillation: An ASPERA-R inverse probability-weighted analysis. J Neurol Sci. 2026 Oct 15. doi: 10.1016/j.jns.2026.126100. PMID: 42476093.


2. Polymeris AA, et al. Etiology, secondary prevention strategies, and outcomes of breakthrough ischemic stroke in patients with atrial fibrillation. Stroke. 2022;53(11):3332-3342.


3. Seiffge DJ, et al. Management of breakthrough stroke in patients with atrial fibrillation on oral anticoagulants. Lancet Neurol. 2024;23(4):412-424.